On September 22, 2016, the annual international lymphoma special conference was held as scheduled at the 19th national congress of clinical oncology and the 2016 CSCO academic annual conference. International top lymphoma experts from eight countries including the United States, Europe, Japan, and south Korea attended the conference. Dr. Lu Xianping, the president and chief scientific officer of CHIPSCREEN BIOSCIENCES, was invited to attend the conference and make a thematic report.

The theme of this conference is to discuss the research progress in clinical treatment of lymphoma with China as the main body and internation as the auxiliary body. At the meeting, Dr. Lu Xianping made a report on " selective histone deacetylase inhibitors and tumor immunotherapy and its future" to the participants. He introduced the current status of tumor treatment, the apparent genetic characteristics of tumors, new treatment ideas, challenges and research trends faced by tumor treatment, and pointed out that the current precise treatment assisted by molecular typing or the path to achieve long-term benefits for tumor patients will eventually shift from the past single drug treatment to the era of combined treatment. The Chidamide independently developed by CHIPSCREEN BIOSCIENCES is the first selective histone deacetylase inhibitor approved by CFDA and the first orphan drug approved to treat peripheral T-cell lymphoma in China. It is mainly aimed at subtypes 1, 2, 3 in the Class I of HDAC and subtypes 10 of Class Ⅱb and has a regulatory effect on the abnormal epigenetic function of tumors. It can enhance dendritic cells' mechanisms such as presenting and maturing tumor antigens, inhibiting regulatory T-cells ( Treg ) and MDSC cells, and play a role in promoting anti-tumor immunity. At present, Chidamide has already played a role in the United States, Japan and China. Professor Ma Jun, the chairman of the conference and the vice-chairman of CSCO, also said that China's lymphoma treatment started late and there were very few innovative medicines in China. China's self-developed Chidamide has attracted the attention of foreign scholars.

The international lymphoma special meeting lasted for a whole day. Many well-known experts including US Obama and Biden's " moon landing program" and Stephan A.Grupp, the maker of precision medicine, made nearly 20 special presentations for the meeting. At the meeting, domestic and foreign blood tumor colleagues discussed China's lymphoma prevention and treatment work together and shared this splendid academic feast.